Therapeutic strategies aimed at inhibiting NUCB2 may simultaneously suppress tumour growth and enhance anti‐tumour immune responses, representing a particularly compelling approach for addressing the therapeutic challenges posed by GBM. This evidence concerns the gene NUCB2 and neoplasm.